GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Wegovy was first to market but has been losing ground to Eli Lilly's Zepbound in recent months, according to the latest ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

CVS Health ( NYSE: CVS) on Thursday announced plans to discontinue operations in the individual health insurance business, ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

CVS and Novo Nordisk have struck a deal that will see the drugstore chain offering the Wegovy weight-loss drug to customers ...

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...

CVS Caremark announced a partnership with Novo Nordisk (NYSE:NVO) to expand access to Wegovy, a GLP-1 drug for obesity, at a ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...